featured
2014 Top Stories in Cardiology: Spotlight on Ezetimibe and Its Target, the Cholesterol Transporter NPC1L1
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201-1204.
- Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102(23):8132-8137.
-
Cannon CP. IMPROVE-IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Paper presented at: American Heart Association Scientific Sessions; 2014; Chicago, IL.
-
Blazing MA, Giugliano RP, DeLemos J, et al. On-treatment analysis of the IMProved reduction of outcomes: Vytorin efficacy international trial (IMPROVE-IT). Paper presented at: American Heart Association Scientific Sessions; 2014; Chicago, IL.
- Myocardial Infarction Genetics Consortium I, Stitziel NO, Won HH, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072-2082.
Disclosure statements are available on the authors' profiles: